No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CRDF240517P5000
- 1.50
- -0.29-16.20%
15min DelayTrading May 9 10:22 ET
1.50High1.50Low
1.50Open1.79Pre Close50 Volume409 Open Interest5.00Strike Price7.50KTurnover0.00%IV0.14%PremiumMay 17, 2024Expiry Date1.58Intrinsic Value100Multiplier8DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma2.17Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- 1D
News
Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036
The incidence of pancreatic cancer is increasing globally, which is driving the growth of the market. As of 2023, the American Cancer Society...
HC Wainwright & Co. Reiterates Buy on Cardiff Oncology, Maintains $14 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cardiff Oncology (NASDAQ:CRDF) with a Buy and maintains $14 price target.
Cardiff Oncology Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/06/2024 300% HC Wainwright & Co. → $14 Reiterates Buy → Buy 03/06/2024 300% HC Wainwright & Co. $12 → $
Cardiff Oncology First Quarter 2024 Earnings: Beats Expectations
Earnings Call Summary | Cardiff Oncology(CRDF.US) Q1 2023 Earnings Conference
The following is a summary of the Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript:Financial Performance:Cardiff Oncology reported a total of $67.2 million in cash and short-term investm
Cardiff Oncology, Inc. (NASDAQ:CRDF) Q1 2023 Earnings Call Transcript
Comments
$Cardiff Oncology(CRDF.US$ + (HOLO-LYT-PIXY...) KEEP BUYING, THEN THEY MUST GO DOWN (TO $1 AND DELETE) BECAUSE CHEATERS BLOCK SHORT = LAO TRAP TRADERS ONE WAY TO HELL 😭👹😡👊👎
$Cardiff Oncology(CRDF.US$ back again in my 👀 testing 4.50
Cardiff Oncology Inc. Skyrockets, Piper Sandler Sets $7 Price Target.
In a significant development that has caught the attention of investors, Cardiff Oncology Inc. (NASDAQ: CRDF) saw an impressive 24% surge in their stock price yesterday, closing at $3.58. This sudden upswing comes amidst positive sentiments from leading investment banking and institutional securities firm, Piper Sandler, which has set a bullish price target of ...
In a significant development that has caught the attention of investors, Cardiff Oncology Inc. (NASDAQ: CRDF) saw an impressive 24% surge in their stock price yesterday, closing at $3.58. This sudden upswing comes amidst positive sentiments from leading investment banking and institutional securities firm, Piper Sandler, which has set a bullish price target of ...
$Cardiff Oncology(CRDF.US$ changed my mindset , protecting money intelligently ! out from here smallest gains mattters then home run 🤘🏻
🤘🏻
🤘🏻
Read more